60 / 320
624
for implementation. Int J Antimicrob Agents 2014;43:105-13.
16. Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of
piperacillin-tazobactam for the treatment of Pseudomonas
aeruginosa infections: prolonged or continuous infusion?
Pharmacotherapy 2007;27:1490-7.
17. Lodise TP Jr, Lomaestro BM, Drusano GL. Piperacillin-
tazobactam for Pseudomonas aeruginosa infection: clinical
implications of an extended-infusion dosing strategy. Clin
Infect Dis 2007;44:357-63.
18. Grupper M, Kuti JL, Nicolau DP. Continuous and prolonged
intravenous beta-lactam dosing: implications for the clinical
laboratory. Clin Microbiol Rev 2016;29:759-72.
19. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion
of beta-lactam antibiotics in severe sepsis: a multicenter,
double-blind, randomized controlled trial. Clin Infect Dis
2013;56:236-44.
20. Dulhunty JM, Roberts JA, Davis JS, et al. A multicenter
randomized trial of continuous versus intermittent beta-
lactam infusion in severe sepsis. Am J Respir Crit Care Med
2015;192:1298-305.
21. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application
of fluoroquinolone pharmacodynamics. J Antimicrob
Chemother 2000;46:669-83.
22. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC,
Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin
in seriously ill patients. Antimicrob Agents Chemother
1993;37:1073-81.
23. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB,
Pierce PF. Pharmacodynamics of fluoroquinolones against
Streptococcus pneumoniae in patients with community-
acquired respiratory tract infections. Antimicrob Agents
Chemother 2001;45:2793-7.
24. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn
J. Relationship between fluoroquinolone area under the curve:
minimum inhibitory concentration ratio and the probability
of eradication of the infecting pathogen, in patients with
nosocomial pneumonia. J Infect Dis 2004;189:1590-7.
25. Deryke CA, Kuti JL, Nicolau DP. Re-evaluation of current
susceptibility breakpoints for Gram-negative rods based on
pharmacodynamic assessment. Diagn Microbiol Infect Dis
2007;58:337-44.
26. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin
therapeutic
guidelines:
a
summary
of
consensus
recommendations from the Infectious Diseases Society of
America, the American Society of Health-System Pharmacists,
and the Society of Infectious Diseases Pharmacists. Clin Infect
Dis 2009;49:325-7.
27. Neely MN, Youn G, Jones B, et al. Are vancomycin trough
concentrations adequate for optimal dosing? Antimicrob
Agents Chemother 2014;58:309-16.
28. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines
by the Infectious Diseases Society of America for the treatment
of methicillin-resistant Staphylococcus aureus infections in
adults and children. Clin infect Dis 2011;52:1-38.
29. Koomanachai P, Kim A, Nicolau DP. Pharmacodynamic
evaluation of tigecycline against Acinetobacter baumannii
in a murine pneumonia model. J Antimicrob Chemother
2009;63:982-7.
30. Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological
and patient-specific response determinants in patients
with hospital-acquired pneumonia treated with tigecycline.
Antimicrob Agents Chemother 2012;56:1065-72.
31. Cheng A, Chuang YC, Sun HY, et al. Excess mortality
associated
with
colistin-tigecycline
compared
with
colistin-carbapenem combination therapy for extensively
drug-resistant Acinetobacter baumannii bacteremia: a
multicenter prospective observational study. Crit Care Med
2015;43:1194-204.
32. De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline
in critically ill patients with severe infections due to multidrug-
resistant bacteria. Crit Care 2014;18:R90.
33. Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics
and pharmacodynamics of ‘old’ polymyxins: what is new?
Diagn Microbiol Infect Dis 2012;74:213-23.
34. Garonzik SM, Li J, Thamlikitkul V, et al. Population
pharmacokinetics of colistin methanesulfonate and formed
colistin in critically ill patients from a multicenter study
provide dosing suggestions for various categories of patients.
Antimicrob Agents Chemother 2011;55:3284-94.
35. Nation RL, Garonzik SM, Li J, et al. Updated US and European
dose recommendations for intravenous colistin: how do they
perform? Clin Infect Dis 2016;62:552-8.
36. Sandri AM, Landersdorfer CB, Jacob J, et al. Population
pharmacokinetics of intravenous polymyxin B in critically ill
patients: implications for selection of dosage regimens. Clin
Infect Dis 2013;57:524-31.
37. Nelson BC, Eiras DP, Gomez-Simmonds A, et al. Clinical
outcomes associated with polymyxin B dose in patients
with bloodstream infections due to carbapenem-resistant
Gram-negative
rods.
Antimicrob
Agents
Chemother
2015;59:7000-6.
38. Cheah SE, LiJ, Tsuji B, Forrest A, Bulitta JB, Nation RL. Colistin
and polymyxin B dosage regimens against Acinetobacter
baumannii: differences in activity and the emergence of
resistance. Antimicrob Agents Chemother 2016;60:3921-33.
39. Nicasio AM, Eagye KJ, Nicolau DP, et al. Pharmacodynamic-
based clinical pathway for empiric antibiotic choice in
patients with ventilator-associated pneumonia. J Crit Care
2010;25:69-77.
40. Nicasio Am, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Length of stay
and hospital costs associated with a pharmacodynamic-based
clinical pathway for empiric antibiotic choice for ventilator-
associated pneumonia. Pharmacotherapy 2010;30:453-62.
[REV. MED. CLIN. CONDES - 2016; 27(5) 615-624]